ModernaTX, Inc. is advancing its mRNA-1647 cytomegalovirus vaccine through a Phase 2 clinical trial, focusing on both CMV-seronegative and CMV-seropositive healthy adults aged 18-40. The successful development of this vaccine could address a significant unmet need in CMV prevention, particularly in populations at risk of congenital CMV infection. The market potential is substantial, given the prevalence of CMV and the lack of approved vaccines. Competitive analysis indicates that while several companies are exploring CMV vaccines, Moderna's mRNA platform provides a technological edge, potentially leading to faster development timelines and robust immune responses. Diligence should focus on safety data, immunogenicity results, and the regulatory pathway as the trial progresses towards pivotal Phase 3 studies.